ArticleCardiovascular diabetology. Endocrinology reports2026
Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide.
Article in Cardiovascular diabetology. Endocrinology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05193578. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
Open the trial in the graphWho cites it
1 citing paper in PubMed.
- Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal.Diabetology & metabolic syndrome · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with schizophrenia suffer from reduced life expectancy, primarily due to obesity-related metabolic disorders and cardiovascular disease (CVD). The presence of cardiac autonomic neuropathy (CAN) may contribute to CVD, but CAN is reversible, and it may improve following weight loss. Semaglutide, a GLP-1 receptor agonist (GLP-1RA), induces weight loss and improves cardio-metabolic risk factors. Therefore, this study evaluated the impact of semaglutide on CAN in individuals with schizophrenia.
methodsWe conducted a double-blind, randomized, placebo-controlled trial with 154 adults (18–60 years, BMI ≥27 kg/m2) who were receiving treatment with second-generation antipsychotics (SGAs) for schizophrenia and prediabetes (HbA1c: 39–47 mmol/mol). Participants were randomized (1:1) to receive once-weekly semaglutide or placebo (titrated to 1.0 mg or maximally tolerated dose) for 30 weeks.
resultsA total of 141 participants completed the trial (semaglutide: 74; placebo: 67). CAN prevalence was high (84%), with 50% of the participants showing definite CAN. CAN prevalence increased with obesity: the risk of having definite CAN increased significantly from BMI 30–35 kg/m2 and to BMI > 35 kg/m2 (p < 0.001). Clozapine treatment was associated with CAN (p < 0.001). Semaglutide treatment for 30 weeks reduced BMI by 2.86 kg/m2 but did not alter CAN levels (p = 0.516). No significant changes were observed in the placebo group.
interpretationCAN is highly prevalent in patients with schizophrenia, and CAN correlates with BMI and clozapine treatment. Although semaglutide reduced BMI, CAN remained unchanged, despite its relationship with BMI. Thus, longer periods with semaglutide treatment may be required before CAN improves.
trial registrationClinicaltrials.gov identifier: NCT05193578.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.